Company Overview
CG Oncology, Inc. operates as a late-stage clinical biopharmaceutical entity focused on the development and commercialization of cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy specifically designed for patients with bladder cancer in the United States. The company functions within the broader Healthcare sector, specifically targeting the Biotechnology industry, which implies a focus on high-risk, high-reward research and development phases aimed at bringing novel therapies to market. As of the latest data, the organization maintains a market capitalization of $5.56B, generates annual revenue of $4.04M, and employs 142 individuals to execute its strategic initiatives. These valuation and revenue figures suggest a company with significant market capitalization relative to its current revenue generation, indicating that the market is pricing in substantial future potential or asset value rather than current operational profitability.
Financial Health
The company reports a trailing twelve-month revenue of $4.04M, a net income of $-160,995,008, and an EBITDA of $-189,328,992, highlighting a substantial divergence between top-line sales and bottom-line profitability. The gap between the $4.04M revenue and the $-160,995,008 net income reveals an extremely aggressive cost structure where operating expenses far exceed current sales volume, a common characteristic in early-to-mid stage biotechnology firms. Free cash flow stands at $-87,615,752, indicating that the company is currently burning cash to fund its clinical trials and development activities rather than generating liquid returns from operations. Despite the negative cash flow, the balance sheet holds $742.16M in cash against only $7.02M in debt, providing a robust buffer for ongoing research expenditures. The debt-to-equity ratio of 0.93 further contextualizes this position, showing that while there is leverage, it is significantly outweighed by available cash reserves. Margin analysis shows a gross margin of 0.0%, an operating margin of -2097.3%, and a profit margin of 0.0%, all of which reflect the pre-revenue or pre-commercialization stage where no gross profit is realized on sales and operating losses are magnified by high fixed costs. Liquidity is supported by a current ratio of 24.63, which indicates an exceptionally strong ability to meet short-term obligations with current assets. Return on Equity is -21.7% and Return on Assets is -15.4%, metrics that reveal management is currently deploying capital in a manner that results in negative returns, consistent with the capital-intensive nature of developing late-stage drug candidates.
Valuation Assessment
Valuation metrics present a complex picture where the trailing P/E ratio is N/A due to negative earnings, while the forward P/E is -35.51, implying that the market expects earnings to remain negative in the immediate future. The price-to-book ratio stands at 7.06, indicating that the market values the company at a significant premium over its tangible book value, likely driven by the potential value of its intellectual property and pipeline assets. Alternative valuation measures include a price-to-sales ratio of 1376.46 and an EV/EBITDA of -25.49, suggesting that traditional multiple-based comparisons are distorted by the lack of profitability and that valuation is driven almost entirely by speculative expectations of future commercial success. The stock has traded between a 52-week low of $14.80 and a 52-week high of $69.35, meaning the current trading price sits at 43.4% below the 52-week high. The beta value of 1.19 indicates that the stock price is approximately 19% more volatile than the broader market, reflecting the heightened risk associated with single-asset biotechnology companies dependent on clinical trial outcomes.
Growth & Income
Revenue growth year-over-year has reached 409.2%, demonstrating a rapid expansion in sales, whereas earnings growth is N/A due to the absence of positive net income. Because the company is not currently profitable, the rate at which earnings are growing is not applicable, but the massive revenue increase suggests rapid scaling of commercial operations or sales initiatives. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available earnings, if any, and the substantial cash reserves are being reinvested into growth initiatives rather than distributed to shareholders. Consequently, the overall growth and income profile is characterized by aggressive revenue expansion funded by cash reserves, with no current income distribution to investors, relying entirely on the successful commercialization of cretostimogene grenadenorepvec to eventually generate profitability.